Credit Suisse analyst Matt Miksic said Johnson & Johnson's voluntary recall of a single lot of its baby powder was an "unwelcome surprise" for investors. However, despite the opportunity to take wider action, as the company did with Tylenol in 1982, J&J has chosen at this point to stand by its assertion that the baby powder does not contain asbestos, noted Miksic. On a related call, the company said the test results for the sample which triggered the recall are inconsistent with historical testing of the U.S. mine from which the lot was produced, which it said had been confirmed by third-party validation. Miksic, who continues to expect increasing clarity and reduced uncertainty around the range of potential liabilities facing the company, reiterated his Outperform rating and $158 price target on J&J shares.